OTCMKTS:PXSLY Pharmaxis (PXSLY) Stock Price, News & Analysis → Claim Your FREE 'AI Income Playbook' Now! (From The Oxford Club) (Ad) Free PXSLY Stock Alerts $0.88 0.00 (0.00%) (As of 06/8/2021) Add Compare Share Share Today's Range$0.88▼$0.8850-Day Range$0.88▼$0.8852-Week Range$0.62▼$1.47VolumeN/AAverage Volume1,000 shsMarket Capitalization$26.53 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Pharmaxis alerts: Email Address Ad The Oxford ClubClaim Your FREE "AI Income Playbook" Now!Income expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Playbook" - and it's yours FREE!Click here now to claim your FREE copy of Marc's AI playbook. About Pharmaxis Stock (OTCMKTS:PXSLY)Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.Read More PXSLY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PXSLY Stock News HeadlinesJune 14 at 1:54 AM | americanbankingnews.comPharmaxis (OTCMKTS:PXSLY) versus Northwest Biotherapeutics (OTCMKTS:NWBO) Financial SurveyOctober 5, 2021 | feeds.benzinga.comProactive news headlines including Aurumin, PolarX, Valor Resources and Hartshead ResourcesSee More Headlines Receive PXSLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharmaxis and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:PXSLY CUSIPN/A CIK1301357 Webwww.pharmaxis.com.au Phone61-2-9454-7200FaxN/AEmployees69Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio2.82 Current Ratio3.31 Quick Ratio2.92 Sales & Book Value Annual Sales$8.75 million Price / Sales3.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book22.00Miscellaneous Outstanding Shares30,150,000Free FloatN/AMarket Cap$26.53 million OptionableNot Optionable Beta1.22 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. Gary Jonathan Phillips (Age 60)CEO, MD & Director Comp: $375.28kMr. David Morris McGarvey BA (Age 65)CA, CPA, CFO & Company Sec. Comp: $309.66kDr. Wolfgang G. Jarolimek Ph.D. (Age 57)B.Sc. Ph.D., Head of Drug Discovery Comp: $304.82kMs. Kristen Morgan B.Sc. (Age 49)BSc, PGDipBusAdmin, MMedSc, Alliance Management - Head of Medical & Regulatory Affairs Comp: $168.68kDr. Brett Charlton Ph.D. (Age 65)MBBS Ph.D., Medical Director Comp: $304.7kMr. Cameron David Billingsley (Age 44)Gen. Counsel Dr. Dieter HamprechtHead of Chemistry for Drug DiscoveryMore ExecutivesKey CompetitorsAffimedNASDAQ:AFMDAssertioNASDAQ:ASRTVistagen TherapeuticsNASDAQ:VTGNDiaMedica TherapeuticsNASDAQ:DMACConnect BiopharmaNASDAQ:CNTBView All Competitors PXSLY Stock Analysis - Frequently Asked Questions How have PXSLY shares performed in 2024? Pharmaxis' stock was trading at $0.88 at the beginning of the year. Since then, PXSLY shares have increased by 0.0% and is now trading at $0.88. View the best growth stocks for 2024 here. How do I buy shares of Pharmaxis? Shares of PXSLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PXSLY) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharmaxis Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharmaxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.